MarketCapExport financials
Ayala Pharmaceuticals (AYLA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Ayala Pharmaceuticals Financial Ratios 2022-2011 | AYLA
Brief overview of Ayala Pharmaceuticals's valuation multiples
The review covers five available annual periods spanning 2020 to 2022.
Market valuation is represented by P/S 11.16x (median 23.33x), P/B 0.99x (median 1.99x). On average, this basket is 51.1% below its own five-year medians. The market values the business at a discount to recent history.
Current measures of operating quality are ROE 34.6%, ROA -4.9%, ROCE 34.1%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
Overall assessment
Ayala Pharmaceuticals's valuation is lower, but weak quality metrics call for caution. Recovery in earnings and capital returns is the key catalyst.
Annual Financial Ratios Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.2 | -2.0 | -4.2 | - | - | - | - | - | - | - | - | - |
P/S |
11.2 | 23.3 | 34.5 | - | - | - | - | - | - | - | - | - |
EPS |
-2.5 | -2.8 | -3.1 | -3.6 | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
5.32 M | 44.8 M | 93.5 M | -11.1 M | 49 M | - | - | - | - | - | - | - |
EBITDA per Share |
-2.42 | -2.71 | -3 | -3.53 | - | - | - | - | - | - | - | - |
EV/EBITDA |
-0.1 | -1.1 | -3.2 | 0.6 | - | - | - | - | - | - | - | - |
PEG |
- | - | 0.08 | - | - | - | - | - | - | - | - | - |
P/B |
1.0 | 2.0 | 3.3 | - | - | - | - | - | - | - | - | - |
P/CF |
-0.2 | -2.1 | -4.7 | - | - | - | - | - | - | - | - | - |
ROE % |
3458.87 | -117.85 | -78.51 | 45.71 | - | - | - | - | - | - | - | - |
ROA % |
-489.29 | -97.88 | -65.78 | -88.72 | - | - | - | - | - | - | - | - |
ROCE % |
3412.47 | -113.17 | -76.45 | 45.86 | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | 6.2 | 3.6 | - | - | - | - | - | - | - | - |
DSO |
61.7 | 35.4 | 56.6 | 36.7 | - | - | - | - | - | - | - | - |
DPO |
2211.2 | 361.3 | 327.2 | 415.0 | - | - | - | - | - | - | - | - |
Operating Cycle |
61.7 | 35.5 | 56.6 | 36.7 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
-2149.5 | -325.8 | -270.6 | -378.3 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Ayala Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | -0.66 | -0.54 | -0.66 | - | -0.68 | -0.75 | -0.74 | - | -0.59 | -0.74 | -1.32 | - | -1.01 | -0.76 | -0.71 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | -0.64 | -0.51 | -0.64 | - | -0.65 | -0.73 | -0.7 | - | -0.56 | -0.72 | -1.28 | - | -0.99 | -0.75 | -0.72 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-212.55 | -237.43 | -137.91 | -108.67 | -68.27 | -84.12 | -71.68 | -31.74 | -13.70 | -0.73 | 24.84 | 46.37 | 31.78 | 12.97 | 9.72 | 9.09 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-138.34 | -159.75 | -110.67 | -92.65 | -59.93 | -73.86 | -63.58 | -84.74 | -68.58 | -93.75 | -98.68 | -105.20 | -61.68 | -25.17 | -18.86 | -17.65 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-200.90 | -224.89 | -131.69 | -104.82 | -65.86 | -81.23 | -69.37 | -30.33 | -13.09 | -0.26 | 24.87 | 46.33 | 31.91 | 12.83 | 9.76 | 9.32 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | 196.0 | 1080.6 | 63.6 | - | 95.0 | 65.8 | 39.8 | - | 98.8 | 80.2 | 67.0 | - | 50.6 | 50.2 | 80.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | 2797.7 | 6985.4 | 716.4 | - | 417.6 | 349.9 | 315.2 | - | 500.0 | 302.4 | 286.4 | - | 549.8 | 1666.5 | 503.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 196.0 | 1080.6 | 63.6 | - | 95.0 | 65.8 | 39.8 | - | 94.4 | 59.5 | 52.4 | - | 50.6 | 50.2 | 80.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | -2601.6 | -5904.8 | -652.8 | - | -322.6 | -284.1 | -275.4 | - | -422.3 | -265.9 | -250.6 | - | -499.1 | -1616.2 | -422.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Ayala Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
